Real-World Comparison of Trifluridine-Tipiracil with or Without Bevacizumab in Patients with Refractory Metastatic Colorectal Cancer.

Additionally, poor performance status (HR = 1.56, 95% CI, 0.96–2.53; p = 0.071) showed a trend toward an association with shorter PFS.

also in 53,322 other papers

Second, the relatively small patient cohort and the multiple statistical comparisons conducted increased the risk of type I errors; thus, statistically significant findings, especially those approaching significance thresholds, require careful interpretation.

also in 2,640 other papers